Nadine Aschmoneit

Generation of a highly versatile TCR bispecific scaffold optimized for targeting tumor-specific peptide-HLA antigens

ABSTRACT Redirection of T lymphocytes toward cancer cells has been one of the most promising treatment concepts in oncology developed over the past years and leading to multiple regulatory approvals for both adoptive cell therapy (ACT) and T-cell-engaging bispecific (TEB) molecules. However, progress has been achieved...